Recent analyses have deepened understanding of neurotoxic events associated with CAR‑T cell therapies and outlined approaches to reduce incidence and severity. Investigators reviewed clinical markers, timing and proposed management protocols to distinguish immune‑mediated neurotoxicity from other neurologic complications after CAR‑T infusion. The work synthesizes data across multiple CAR constructs and patient cohorts, offering operational guidance for hematology teams and trialists designing safer next‑generation cellular therapies. CAR‑T neurotoxicity refers to neurologic adverse events linked to immune activation following engineered T‑cell treatments.